Literature DB >> 1227297

Naltrexone pharmacology, pharmacokinetics, and metabolism: current status.

K Verebey, S J Mulé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1227297     DOI： 10.3109/00952997509005661

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN： 0095-2990            Impact factor:   3.829


× No keyword cloud information.
  10 in total

1.  Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse.

Authors:  Jinmin Zhu; Thomas J Spencer; Lee-Yuan Liu-Chen; Joseph Biederman; Pradeep G Bhide
Journal:  Neuropharmacology       Date:  2011-04-23       Impact factor: 5.250

2.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

Authors:  Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman
Journal:  Arch Gen Psychiatry       Date:  2008-02

3.  Long-acting injectable naltrexone for the management of patients with opioid dependence.

Authors:  Kimberly L Kjome; F Gerard Moeller
Journal:  Subst Abuse       Date:  2011-02-06

Review 4.  Opioid antagonists in the treatment of alcohol dependence.

Authors:  G O'Leary; J Borrow; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

5.  μ Opioid Antagonist Naltrexone Partially Abolishes the Antidepressant Placebo Effect and Reduces Orbitofrontal Cortex Encoding of Reinforcement.

Authors:  Marta Peciña; Jiazhou Chen; Thandi Lyew; Jordan F Karp; Alexandre Y Dombrovski
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2021-03-06

6.  Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.

Authors:  Gantt P Galloway; Monika Koch; Ryan Cello; David E Smith
Journal:  BMC Psychiatry       Date:  2005-04-01       Impact factor: 3.630

7.  Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.

Authors:  Laurel S Morris; Kwangyeol Baek; Roger Tait; Rebecca Elliott; Karen D Ersche; Remy Flechais; John McGonigle; Anna Murphy; Liam J Nestor; Csaba Orban; Filippo Passetti; Louise M Paterson; Ilan Rabiner; Laurence Reed; Dana Smith; John Suckling; Eleanor M Taylor; Edward T Bullmore; Anne R Lingford-Hughes; Bill Deakin; David J Nutt; Barbara J Sahakian; Trevor W Robbins; Valerie Voon
Journal:  Addict Biol       Date:  2017-02-28       Impact factor: 4.280

8.  Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses.

Authors:  Martiniano Bello
Journal:  Molecules       Date:  2022-08-02       Impact factor: 4.927

9.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

Review 10.  The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.

Authors:  Jarred Younger; Luke Parkitny; David McLain
Journal:  Clin Rheumatol       Date:  2014-02-15       Impact factor: 2.980
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.